These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18989952)

  • 1. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
    Di Fabio R; St-Denis Y; Sabbatini FM; Andreotti D; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Di Modugno E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Provera S; Marchioro C; Roberts KL; Mingardi A; Mattioli M; Nalin A; Pavone F; Spada S; Trist DG; Worby A
    J Med Chem; 2008 Dec; 51(23):7370-9. PubMed ID: 18989952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
    Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
    J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
    Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW
    J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
    J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
    Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
    Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.
    St-Denis Y; Di Fabio R; Bernasconi G; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Ghirlanda D; Marchionni C; Messina F; Micheli F; Pavone F; Pasquarello A; Sabbatini FM; Zampori MG; Arban R; Vitulli G
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3713-6. PubMed ID: 15946843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power spectrum analysis of ultrasonic vocalization elicited by maternal separation in rat pups.
    Ise S; Ohta H
    Brain Res; 2009 Aug; 1283():58-64. PubMed ID: 19523931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin releasing factor enhances attentional function as assessed by the five-choice serial reaction time task in rats.
    Ohmura Y; Yamaguchi T; Futami Y; Togashi H; Izumi T; Matsumoto M; Yoshida T; Yoshioka M
    Behav Brain Res; 2009 Mar; 198(2):429-33. PubMed ID: 19084036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
    Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
    Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.